Johnson & Johnson stated Tuesday it will collaborate with Apple on research to use an iPhone app and the Apple Watch to review how earlier detection of atrial fibrillation affects stroke in people aged 65 or older.
In 2019, Apple’s Heart Study discovered that the watch could precisely detect atrial fibrillation, the most common type of irregular heartbeat, based on a study that explored the role of wearable gadgets in figuring out potential heart problems.
Jeff Williams, Apple’s chief operating officer (COO), stated the preliminary study proved the Apple Watch can record atrial fibrillation with a low rate of false alarms, which helped Apple gain clearance from the U.S. Food and Drug Administration (FDA) for a watch application that takes an electrocardiogram, or EKG, measurement. The research with J&J aims to point out if early detection results in better health outcomes.
The joint effort referred to as “Heartline” is vital because J&J is one of the world’s largest medical gadget manufacturers and pharmaceutical corporations.
The study may reach a different population than Apple’s previous heart study, which involved 400,000 contributors.
J&J targeted the study at the population with a higher risk.
The J&J research will be open to over 40 million participants signed-up for traditional Medicare programs, which cover people aged 65 and older in addition to the disabled. Study contributors can be randomly assigned to either use only an iPhone app or use the app alongside a watch capable of noting an EKG.
If patients who enroll are put to the branch of the study utilizing the Apple Watch, they will be prompted to acquire one of many devices.
The newest Apple Watch version starts at $399.